Human immunodeficiency virus envelope V1 and V2 regions influence replication efficiency in macrophages by affecting virus spread.
about
HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradationThe interferon response inhibits HIV particle production by induction of TRIM22Human HERC5 restricts an early stage of HIV-1 assembly by a mechanism correlating with the ISGylation of GagThe dimerization domain of HIV-1 viral infectivity factor Vif is required to block virion incorporation of APOBEC3GAPOBEC3G contributes to HIV-1 variation through sublethal mutagenesisA lectin isolated from bananas is a potent inhibitor of HIV replicationDefinition of the stage of host cell genetic restriction of replication of human immunodeficiency virus type 1 in monocytes and monocyte-derived macrophages by using twins.Allosteric modulation of the HIV-1 gp120-gp41 association site by adjacent gp120 variable region 1 (V1) N-glycans linked to neutralization sensitivityInhibition of HIV-1 replication by balsamin, a ribosome inactivating protein of Momordica balsaminaPatients infected with CRF07_BC have significantly lower viral loads than patients with HIV-1 subtype B: mechanism and impact on disease progressionEffects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1.Functional characteristics of HIV-1 subtype C compatible with increased heterosexual transmissibility.HIV-1 envelope subregion length variation during disease progressionInterferon-induced HERC5 is evolving under positive selection and inhibits HIV-1 particle production by a novel mechanism targeting Rev/RRE-dependent RNA nuclear export.A helical flow, circular microreactor for separating and enriching "smart" polymer-antibody capture reagents.IFN-alpha-induced upregulation of CCR5 leads to expanded HIV tropism in vivoHIV-1 envelope determinants for cell tropism and chemokine receptor use.Palmitic Acid Is a Novel CD4 Fusion Inhibitor That Blocks HIV Entry and Infection.Variants of human immunodeficiency virus type 1 that efficiently use CCR5 lacking the tyrosine-sulfated amino terminus have adaptive mutations in gp120, including loss of a functional N-glycanRole of low CD4 levels in the influence of human immunodeficiency virus type 1 envelope V1 and V2 regions on entry and spread in macrophagesHIV-1 Transmission, Replication Fitness and Disease Progression.Determinants of entry cofactor utilization and tropism in a dualtropic human immunodeficiency virus type 1 primary isolate.Neuronal death induced by brain-derived human immunodeficiency virus type 1 envelope genes differs between demented and nondemented AIDS patientsHuman immunodeficiency virus type 1 coreceptor preferences determine target T-cell depletion and cellular tropism in human lymphoid tissueDeterminants of syncytium formation in microglia by human immunodeficiency virus type 1: role of the V1/V2 domainsParameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides.Role of naturally occurring basic amino acid substitutions in the human immunodeficiency virus type 1 subtype E envelope V3 loop on viral coreceptor usage and cell tropismPatterns of chemokine receptor fusion cofactor utilization by human immunodeficiency virus type 1 variants from the lungs and blood.Genetic variation and HIV-associated neurologic disease.Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate.Cytopathicity of human immunodeficiency virus type 1 primary isolates depends on coreceptor usage and not patient disease statusHuman immunodeficiency virus type 1 Nef functions at the level of virus entry by enhancing cytoplasmic delivery of virions.Two ribosome recruitment sites direct multiple translation events within HIV1 Gag open reading frame.Production of infectious human papillomavirus independently of viral replication and epithelial cell differentiation.The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner.Inhibition of HIV-1 infection in ex vivo cervical tissue model of human vagina by palmitic acid; implications for a microbicide development.Reduced fitness in cell culture of HIV-1 with nonnucleoside reverse transcriptase inhibitor-resistant mutations correlates with relative levels of reverse transcriptase content and RNase H activity in virions.Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations.Partial rescue of V1V2 mutant infectivity by HIV-1 cell-cell transmission supports the domain's exceptional capacity for sequence variation.Coreceptor phenotype of natural human immunodeficiency virus with nef deleted evolves in vivo, leading to increased virulence.
P2860
Q21089617-B6357E33-3551-49A4-BFA4-B9003C7DE265Q21131598-60CE8EC9-AA68-489C-A4A6-26BF00E9E0A8Q21245043-2578A51C-5AEA-4C54-8EED-0418B2437F75Q21245195-537E2E1D-9CA1-4A69-98ED-1ED38D25FF78Q24618320-C88559D5-C4FB-40E5-80B1-88A772BA29A3Q24629155-7C6A8318-F25A-4691-A396-DF3A355114CBQ27469707-180386FD-52D8-4F2D-9B05-6D0BB95BB71BQ28485983-BE743B5A-3301-4A2A-B2AC-04A069F8C3A6Q28536744-D3488D5B-937D-4F99-8876-A4CE44D45C3DQ28542678-93AEE962-4237-4448-AB5D-BA39C9E9E17BQ29622903-1301FBB0-BA94-473D-9CBD-E6528CA6B88EQ30376421-43835E9A-590B-4BF0-8BB4-930C5BCAEA7EQ30397933-054F9BD4-A2CE-4A61-BC9F-A909F9523B6AQ30413069-CFA0A8CB-4746-42EC-8A49-DD609E3287ECQ30501215-39CAAA58-C484-44CF-810D-3F47A4530101Q33533290-9F307464-C89A-40FC-97F1-B704EED2C4E6Q33637946-C2008E66-CEF8-4252-AEF0-4DA7B4540FE0Q33686657-9D518C69-EAE7-4AB3-8606-FEBA37181CE1Q33707333-0DEEFB6E-F4B2-4821-B6F1-862FA835EB1CQ33724200-F73E91A6-BF34-4880-AD86-D66BFECF556DQ33758570-63A88C58-995E-47CA-BFEF-F85320C91CBFQ33782925-D2597D22-BF8B-4B8B-BF12-64FE9CD636F3Q33785357-2CD3FF31-244D-4E8F-81E4-57E23D474392Q33787161-7A412664-D9D9-4E2F-8B90-D35918697474Q33796067-0857D6D1-72F9-4ECB-BA0A-360607F1AF79Q33805787-302F76E6-078C-4728-8D3C-CEBFC71D2183Q33815193-260F4205-3F1A-4D51-B3A1-40FBBD814BE8Q33817409-9EA182F9-00A8-4483-AA5A-8946B60E3BC5Q33819189-6E0E134E-C766-4A4E-AE76-6F5782A715D9Q33851094-6CA25EBE-AE90-43DA-BF74-9829BED1CC14Q33854835-465E339A-B401-43E4-BAB4-09565F1175A5Q33866230-6F84984C-37BA-44B9-A26D-B71725342ECAQ33878231-7C885DCB-EEB0-4D09-9785-1D7AABF6B474Q33879132-600EB93D-B6B1-4639-B663-9083721B6F71Q33883936-4098C76F-B567-401D-9837-DB19D60FDCEBQ34031472-7E09A3CB-7FAC-420E-BA6B-8AD0F7F77410Q34120147-4D540AEE-C11A-4B92-8D89-963600B92809Q34301803-C011CE64-CE44-4596-8F29-891078D0FF19Q34309493-01BF453E-CC9C-4092-B452-0388A212F6C4Q34342429-2967472A-BAC2-4CF7-ACFD-3542137F5C73
P2860
Human immunodeficiency virus envelope V1 and V2 regions influence replication efficiency in macrophages by affecting virus spread.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Human immunodeficiency virus e ...... ges by affecting virus spread.
@en
Human immunodeficiency virus e ...... ges by affecting virus spread.
@nl
type
label
Human immunodeficiency virus e ...... ges by affecting virus spread.
@en
Human immunodeficiency virus e ...... ges by affecting virus spread.
@nl
prefLabel
Human immunodeficiency virus e ...... ges by affecting virus spread.
@en
Human immunodeficiency virus e ...... ges by affecting virus spread.
@nl
P2093
P356
P1433
P1476
Human immunodeficiency virus e ...... ges by affecting virus spread.
@en
P2093
P356
10.1006/VIRO.1995.1547
P407
P577
1995-10-01T00:00:00Z